Asimov
Asimov, located in Boston, MA, offers advanced genetic design products and services, including the CHO Edge System, LV Edge System, and AAV Edge System. The company integrates synthetic biology with computational tools and partners with over 25 companies, including top-10 pharmas.
Company Overview
Asimov is based in Boston, MA, with its office at 201 Brookline Avenue, Suite 1201. The company specializes in providing an integrated suite of cells, genes, and software for advanced genetic design. Asimov has developed a platform that incorporates synthetic biology with computational tools to enhance genetic design capabilities. They are renowned for their state-of-the-art cell line development services and partnerships with leading pharmaceutical and biotech companies.
Product Offerings
Asimov offers a range of specialized products including the CHO Edge System, LV Edge System, and AAV Edge System. The CHO Edge System utilizes a proprietary CHO host cell line and hyperactive transposase. These products are part of Asimov's efforts to advance biologics, cell and gene therapies, and RNA technologies. Their suite of tools and services aims to streamline and enhance the genetic design process for their users.
Cell Line Development Services
Asimov provides cell line development services using cutting-edge equipment and industry-leading timelines. These services are crucial for companies involved in biologics, cell and gene therapies, and RNA. The company's expertise in this area allows them to offer efficient and reliable services to their partners, helping them accelerate their research and production processes.
Collaborations and Partnerships
Asimov partners with over 25 companies, including top-10 pharmaceutical firms, biotech companies, and contract development and manufacturing organizations. These collaborations enhance Asimov's ability to provide comprehensive solutions to its clients and expand its reach in the biotechnology sector. The partnerships also underscore the reliability and effectiveness of Asimov's tools and services.
Financial Milestones
Asimov has raised $200 million to scale its tools and services business in the fields of biologics, cell and gene therapies, and RNA. This substantial investment underscores the confidence of stakeholders in Asimov's capabilities and future growth potential. The funding will help Asimov expand its offerings and improve its technological infrastructure to better serve its clients.